Nathan P. Lawrence
Nessuna posizione attualmente
Patrimonio netto: 44 $ in data 30/04/2024
Profilo
Nathan P.
Lawrence worked as a Director of Research & Development at Boston Biomedical, Inc. and as a Vice President of Sales & Marketing at Pressure BioSciences, Inc. Lawrence holds a doctorate degree from Yale University, a graduate degree from Southern Connecticut State University, and an undergraduate degree from the University of Miami.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
06/07/2012 | 200 ( 0.14% ) | 44 $ | 30/04/2024 |
Precedenti posizioni note di Nathan P. Lawrence
Società | Posizione | Fine |
---|---|---|
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Direttore Tecnico/Scientifico/R&S | - |
PRESSURE BIOSCIENCES, INC. | Vendite & Marketing | - |
Formazione di Nathan P. Lawrence
University of Miami | Undergraduate Degree |
Southern Connecticut State University | Graduate Degree |
Yale University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
PRESSURE BIOSCIENCES, INC. | Health Technology |
Aziende private | 1 |
---|---|
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Commercial Services |
- Borsa valori
- Insiders
- Nathan P. Lawrence